insights_auto
Why is ABVX up 2.01%?
Dive Deeperchevron_right
ABVX:NASDAQ
Abivax SA
$88.24
arrow_upward
+2.01%(+1.74) 1D
Oct 27, 11:03:14 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
$86.63
High
$89.40
Low
$86.14
Mkt. cap
6.99B
Avg. vol.
1.34M
Volume
147.27K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.55M
No. of employees
98
Open
$86.63
High
$89.40
Low
$86.14
Mkt. cap
6.99B
Avg. vol.
1.34M
Volume
147.27K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
Kitco
·
20 minutes ago
S&P 500, Nasdaq advance as oil eases ahead of Fed decision
TradingView
·
37 minutes ago
Cyber Hornet S&P 500 Index Fund Surpassed $175 Million In Assets Under Management As Of October 27
Investing.com
·
43 minutes ago
S&P at 8,000? Morgan Stanley says a post-election rally is coming
The Motley Fool
·
2 hours ago
Up 16% This Year, How Long Can Procter & Gamble Continue Outperforming the S&P 500?
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com